Photo Credit: Houston MethodistHealth
New GLP-1 research fuels optimism on weight‑loss drugs and mental health, according to Houston Methodist experts
One in eight Americans now report taking a GLP-1 drug, according to health research group KFF. As Houston welcomes a new GLP-1 manufacturing facility, emerging research suggests the medications’ impact may extend beyond the scale to mental health. Houston Methodist obesity medicine specialists said the new research offers optimistic takeaways.
Published by The Lancet, the study found that GLP-1 medications were not linked to worsening mental illness in people with depression and anxiety. In some cases, they were even associated with lower risks of depression, anxiety and substance use disorders.
Janelle Jakobi, an obesity medicine specialist and bariatric physician assistant at Houston Methodist Willowbrook Hospital who routinely cares for patients using these medications, said the observational findings offer hopeful insight for those facing mental health struggles while utilizing weight loss medication.
“These medications don’t just affect weight,” she said. “They also influence parts of the brain involved in appetite, reward and inflammation. When someone’s metabolic health improves, it may also positively affect mood and impulse control.”
Jakobi said that the mental health benefits appeared strongest in people who experienced greater weight loss and metabolic improvements, suggesting the changes may be tied to overall health improvements rather than the medication alone. She said for Houstonians considering or already taking these medications, the findings may offer additional reassurance.
“This data suggests these medications do not harm mental health and may even provide added benefits for people struggling with substance use,” Jakobi said. “While patients should always be monitored closely, the results may support broader and more confident use of these treatments.”
Dr. Todd Worley, an obesity medicine specialist and bariatric surgeon at Houston Methodist Willowbrook Hospital said while the study of mental health outcomes is complex, the research adds to growing interest in how GLP-1 medications may affect the brain.
“There are GLP-1 receptors in the brain, so it’s reasonable to explore whether these medications could help with conditions like depression, anxiety or substance use disorder,” Worley said. “This study doesn’t prove that connection, but there’s enough positive data to justify further research.”
Worley also said the findings suggested fewer hospitalizations and fewer missed workdays among people taking the medications are outcomes that could have meaningful impacts on quality of life.
Both Jakobi and Worley, who were not involved in the research, noted that the study is observational, meaning it shows associations rather than direct cause and effect. They said more studies are needed to fully understand how these medications influence mental health over time.
Still, as use of GLP-1 medication continues to grow across Houston and beyond, Worley and Jakobi said the findings offer encouraging insights for patients and providers alike. Learn more about weight loss medications at houstonmethodist.org.
For more information about Houston Methodist, visit our newsroom or our social media pages on X, Facebook, LinkedIn, Instagram and TikTok or our On Health and Leading Medicine blogs.
Source: Houston Methodist
